InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tectonic Therapeutic, Inc.

TECX Clue Score49
United States Fiscal year ends December CIK 0001681087
$23.33 +2.55% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $23.33 +323.41% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 21 Jun 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2017Operating income−18.4Net income−18.6Fiscal year 2018Operating income−46.2Net income−46.4Fiscal year 2019Operating income−75.8Net income−73.0Fiscal year 2020Operating income−120.2Net income−119.7Fiscal year 2021Operating income−118.8Net income−119.1EPS, diluted−2.78Fiscal year 2022Operating income−105.4Net income−105.9EPS, diluted−2.42Fiscal year 2023Operating income−44.6Net income−42.8EPS, diluted−33.76Fiscal year 2024Operating income−58.0Net income−58.0EPS, diluted−6.83Fiscal year 2025Operating income−84.0Net income−74.2EPS, diluted−4.05
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −18.4 −46.2 −75.8 −120.2 −118.8 −105.4 −44.6 −58.0 −84.0
Net income −18.6 −46.4 −73.0 −119.7 −119.1 −105.9 −42.8 −58.0 −74.2
Growth
EPS, diluted n/a n/a n/a n/a −2.78 −2.42 −33.76 −6.83 −4.05

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−16.4Capital expenditure−0.4Free cash flow−16.8Fiscal year 2018Operating cash flow−37.6Capital expenditure−1.8Free cash flow−39.5Fiscal year 2019Operating cash flow−67.7Capital expenditure−1.6Free cash flow−69.3Fiscal year 2020Operating cash flow−98.8Capital expenditure−1.2Free cash flow−100.0Fiscal year 2021Operating cash flow−98.0Capital expenditure−2.5Free cash flow−100.5Fiscal year 2022Operating cash flow−97.2Capital expenditure−0.3Free cash flow−97.5Fiscal year 2023Operating cash flow−40.7Capital expenditure−0.3Free cash flow−41.0Fiscal year 2024Operating cash flow−59.1Capital expenditure−0.2Free cash flow−59.2Fiscal year 2025Operating cash flow−60.1Capital expenditure−0.2Free cash flow−60.3
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −16.4 −37.6 −67.7 −98.8 −98.0 −97.2 −40.7 −59.1 −60.1
Capital expenditure −0.4 −1.8 −1.6 −1.2 −2.5 −0.3 −0.3 −0.2 −0.2
Free cash flow −16.8 −39.5 −69.3 −100.0 −100.5 −97.5 −41.0 −59.2 −60.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash6.0Shareholders’ equity−23.1Fiscal year 2018Cash126.3Shareholders’ equity122.2Fiscal year 2019Cash187.0Shareholders’ equity186.0Fiscal year 2020Cash259.7Shareholders’ equity254.3Fiscal year 2021Cash189.6Total debt15.0Net cash (debt)174.6Shareholders’ equity169.5Debt to equity0.09Fiscal year 2022Cash92.6Total debt15.0Net cash (debt)77.6Shareholders’ equity−45.7Fiscal year 2023Cash28.8Shareholders’ equity−84.6Fiscal year 2024Cash141.2Shareholders’ equity140.8Fiscal year 2025Cash253.8Shareholders’ equity251.3
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 6.0 126.3 187.0 259.7 189.6 92.6 28.8 141.2 253.8
Total debt n/a n/a n/a n/a 15.0 15.0 n/a n/a n/a
Net cash (debt) n/a n/a n/a n/a 174.6 77.6 n/a n/a n/a
Shareholders’ equity −23.1 122.2 186.0 254.3 169.5 −45.7 −84.6 140.8 251.3
Debt to equity n/a n/a n/a n/a 0.09 n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
15.2 35.1 55.0 87.2 83.1 72.2 37.0 41.4 63.5
3.2 11.1 20.8 33.0 35.7 33.2 7.7 16.7 20.5
−18.4 −46.2 −75.8 −120.2 −118.8 −105.4 −44.6 −58.0 −84.0
Growth
n/a n/a n/a n/a n/a n/a n/a −58.0 −72.9
n/a n/a n/a n/a n/a 0.0 0.0 0.0 1.2
−18.6 −46.4 −73.0 −119.7 −119.1 −105.9 −42.8 −58.0 −74.2
Growth
Per share
n/a n/a n/a n/a −2.78 −2.42 −33.76 −6.83 −4.05
n/a n/a n/a n/a −2.78 −2.42 −33.76 −6.83 −4.05
Growth
n/a n/a n/a n/a 0.0 43.7 1.3 8.5 18.3
n/a n/a n/a n/a 0.0 43.7 1.3 8.5 18.3
Growth +101,965.2% −97.1% +569.3% +115.8%

† The diluted share count jumps at 2022 and 2023 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 9 of 9 years on file.